Datar Cancer Genetics is a multi-national molecular oncology facility focused on innovative test solutions for cancer screening, diagnosis and therapy guidance. Their aim is to help patients through the use of molecular oncology and personalised medicine.
The non-invasive blood-based test portfolio supports clinicians to select personalised therapies that will help improve patient outcomes. Datar Cancer Genetics has received two Breakthrough Device Designations from the US-FDA for its early detection tests for breast and prostate cancer.
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford UK, and the College of American Pathologists (CAP) has granted it accreditation. It is equipped with state-of-the-art machines and analytics. The laboratory is registered with CQC and is an applicant with UKAS.
The centre provides a wide range of services in molecular genomics and Circulating Tumour Cell (CTC) analysis for cancer patients.
You can request testing from your healthcare provider. Alternatively, contact Datar Cancer Genetics and they will put you in touch with their clinical partners.
Cancer screening, diagnosis and therapy guidance products Trucheck™, Cancertrack™, Exacta™, Trublood™ and Celldx™